logo
  

Fulgent Genetics To Acquire Inform Diagnostics, Lifts Q3 Revenue Outlook, Shares Up 5%

Shares of Fulgent Genetics, Inc. (FLGT) gained nearly 5% in extended trading session on Monday after the company announced the acquisition of Inform Diagnostics and lifted its revenue outlook.

Fulgent Genetics agreed to buy Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners, for a total price of about $170 million to be paid from cash on hand.

The acquisition is expected to close during the second quarter of 2022, subject to the satisfaction of customary closing conditions, including regulatory approvals.

Looking forward to the first quarter of 2022, Fulgent now anticipates revenue to be about $300 million, up from prior guidance of $245 million, and core revenue excluding COVID-19 NGS testing to be at least $22 million, consistent with previous guidance.

Analysts polled by Thomson Reuters currently estimate revenues of $244.65 million for the quarter.

FLGT closed Monday's trading at $55.26, down $0.87 or 1.55%, on the Nasdaq. The stock, however, gained $2.49 or 4.51%, in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
RELATED NEWS
Follow RTT